WallSt Focus

Cytokinetics is currently in the midst of a sale process, faces a pivotal crossroads with speculation looming on potential suitors, including the possibility of Novartis returning or alternative avenues.

Even though we are in the beginning of 2024, small-cap stocks have already stolen the spotlight from their larger counterparts, outperforming the big players with a remarkable 16% surge since October ‘23.

Delta Air Lines' recent nosedive stirred investor concern, casting a shadow over the entire travel sector.

Tech player, PagerDuty has entered the spotlight due to a Bloomberg report that unveiled the company's consultation with advisers over a possible sale.

So far, January has been a challenging month for Wall Street, and today was no exception, with investor confidence drooping due to dimming hope of rate interest cuts.

January’s performance so far has been a rollercoaster ride filled with ups and downs. Last week’s turnaround has spurred investor confidence and begs the question: What comes next?

Clinical stage biopharma small-cap, Harpoon Therapeutics has entered the spotlight with pharma giant, Merck agreeing to acquire the company for a staggering $680 million.